Fig. 7.

Overview and clinical scores of sustained SOC-responders and transitioned SOC-refractory patients in typical CIDP patients. A The total amount of patients with the status sustained SOC-responder (patients who still met the SOC-responder status at 12 months follow-up) and sustained SOC-refractory (patients who transitioned to a SOC-refractory status at 12 months follow-up) after 12 months, respectively. B Mean MRC sum scores ± SEM of these patient subgroups after 12, 24 and 36 months, respectively. Data was available from (sustained SOC-responder/transitioned SOC-refractory) 29/15 (at diagnosis), 24/13 (after 12 months), 22/12 (after 24 months) and 20/10 (after 36 months) patients. C, D Mean INCAT arm and leg disability scores ± SEM of the depicted treatment-response cohorts after 12, 24 and 36 months, respectively. Data was available from (sustained SOC-responder/transitioned SOC-refractory) 30/15 (at diagnosis), 27/14 (after 12 months), 23/13 (after 24 months) and 23/11 (after 36 months) patients. CIDP chronic inflammatory demyelinating polyneuropathy, INCAT inflammatory neuropathy cause and treatment, MRC Medical Research Council, SEM standard error of the mean, SOC standard of care